The China International Import Expo, which opened on Sunday, has proven to be a premier platform for companies from around the world to showcase their latest cutting-edge products as proven by the slew of exhibits making their global or regional debut.

In the medical product pavilion, global pharmaceutical and medical device companies are releasing hundreds of innovative products and technologies as exhibitors open the curtains of their booths.

At the booth of United States-based global medical technology company BD, PowerMe?, a Midline Catheter product tailored to meet Chinese clinicians' insertion preferences, made its global debut.

This innovative infusion device addresses the unmet needs of the China market by providing a catheter that can be indwelled for up to 30 days, bridging the gap between short-term and long-term patient infusion treatment. It can significantly improve clinicians' work efficiency and reduce complications in patients.

Another notable healthcare exhibit is Abbott's AVEIR? dual-chamber (DR) leadless pacemaker system, which is making its Asia debut. It is the world's first and currently the only true dual-chamber leadless pacing system that treats people with abnormal or slow heart rhythms.

Femoston? Mini is another pharmaceutical product by US-based Abbott that is making its debut in China. It is used for the treatment of estrogen deficiency in women at least 12 months after menopause.

Siemens Healthineers' first mobile CT that provides head imaging directly at the point of care made its Asia debut at CIIE.

Patients in neurosurgical ICUs suffering from acute and critical head conditions face a high risk of sudden health status deterioration. When this happens, fast evaluation for immediate treatment decision-making is crucial. Although CT scans are ideally suited for this task, transportation of patients to the radiology department may worsen the health condition even more.

SOMATOM On.site is a mobile head CT, which can be freely moved to the bedside of ICU patients. With this easy access to CT imaging of the head, images can be obtained to help diagnose and treat sudden changes in the patient's condition faster.

Biopharmaceutical company Teva spotlights two products that are making China debuts: an innovative migraine therapy, Fremanezumab, and a consumer healthcare product, Sudocrem?.

Fremanezumab offers prophylactic treatment for adults suffering from migraines. The medicine has received authorization from the Guangdong Provincial Medical Products Administration for pilot use in the Guangdong-Hong Kong-Macao Greater Bay Area.